Compared to other immune checkpoint inhibitors, irAE colitis induced by anti-CTLA-4 are frequent, potentially severe and resemble IBD, whereas those induced by PD-1 blockade seem to be less frequent and clinically more diverse. Here, CTLA4 is linked to colitis.